f brain tumours f

final reSultS of regoma: a randomized, multiCenter, Controlled oPen-label PhaSe ii CliniCal trial evaluating regorafenib in relaPSed

glioblaStoma (gbm) PatientS (PtS)

Lombardi G.1_{, De Salvo G.L.}2_{, Rudà R.}3_{, Franceschi E.}4_{, Eoli}

M.5_{, Faedi M.}6_{, Pace A.}7_{, Lolli I.}8_{, Rizzato S.}9_{, Germano D.}10_,

Pasqualetti F.11_{, Farina M.}12_{, Bellu L.}12_{, Caccese M.}12_{, Pambuku}

A.12_{, Bergo E.}12_{, Indraccolo S.}12_{, Gardiman M.P.}13 _{and Soffietti R.}3

1_{Department of Clinical and Experimental Oncology, Medical Oncology 1,}

Veneto Institute of Oncology, IOV-IRCCS,, Padova; 2_{Clinical Trials and Biostatistics}

Unit, Veneto Institute of Oncology-IRCCS, Padua, Padova; 3_{Department of}

Neuro-Oncology, University of Turin and City of Health and Science, Torino; 4

Department of Medical Oncology, Bellaria Hospital, Azienda USL - IRCCS Insti- tute of Neurological Sciences, Bologna; 5_{Besta, Milano;} 6_{IRST, Meldola;} 7 _Neuron-

cology Unit, IFO, Roma; 8_{Medical Oncology Unit, IRCCS Saverio de Bellis,,}

Castellana Grotte; 9_{Dipartimento di Oncologia, Azienda Sanitaria-Universitaria}

Integrata, Udine; 10_{Medical Oncology Unit, Azienda Ospedaliera “G. Rummo”,}

Benevento; 11_{Department of Radiotherapy, Azienda Ospedaliero-Universitaria}

Pisana,, Pisa; 12_{IOV, Padova;} 13_{Unità Anatomia Patologica, Padova}

Background: There is no established treatment regimen for recurrent GBM. GBMs have activation of multiple signaling pathways in the tumor microenvironment, including the receptor tyrosine kinases, VEGFR, FGFR, and PDGFR. REG, an oral multikinase inhibitor, inhibits these angiogenic kinases and the mutant oncogenic kinases KIT, RET, and B-RAF.

Methods: We present, after the first analysis, the final results of REGOMA trial. The primary aim of this trial was to assess REG activity in prolonging overall survival (OS) in PTS with relapsed GBM after surgery and Stupp regi- men (a = 0.2, 1-sided; ß = 0.2). Secondary objectives were PFS, disease control rate (DCR), safety, quality of life (QoL); exploratory objectives included analysis of metabolic tissue biomarkers as possible predictors of response. PTS with histologically confirmed GBM, ECOG PS 0-1, documented disease progression were randomized

1:1 to receive REG 160 mg/day (3 weeks on, 1 week off) or lomustine (LOM) 110 mg/m2 (every 6 weeks) until dis- ease progression or unacceptable toxicity. Tumor response was evaluated by brain MRI every 8 weeks according to the RANO criteria.

Results:119 PTS were randomized (n = 59 REG; n = 60 LOM) and stratified for surgery at recurrence; baseline characteristics, including MGMT methylation status, were balanced. Median age was 57.3 yrs; 27 PTS (22.7%) had surgery at recurrence, 22% and 23.3% in REG and LOM arm. At the time of analysis (cut-off date: Dec 31, 2017), median follow up was 15.4 months(m), 99 PTS had died. Median OS was 7.4m (95% CI 5.8-12.0) for REG and 5.6m (95% CI 4.7-7.3) for LOM (HR = 0.50, 80%CI 0.38- 0.65; p = 0.0007; 1-sided Log-rank test); 12m-OS rates were 38.9% and 15.0% for REG and LOM. 6m-PFS rates were 16.9% and 8.3% (HR = 0.65; 95% CI 0.45-0.95; p = 0.0223) for REG and LOM, DCR was 44.8% and 21.1% (p = 0.009) for REG and LOM. Grade =3 adverse events were reported in 56% and 40% for REG and LOM, no treatment-related deaths were reported.

Conclusions: In this multicenter, randomized study, REG significantly improved OS, PFS and DCR in recurrent GBM PTS. REG treatment was feasible and well tolerated. QoL and biomarker analyses are ongoing. A phase 3 study will be planned.

f02

miSmatCh rePair defiCienCy (mmrd) in glioma PatientS (PtS): frequenCy and Correlation with CliniCal, hiStologiCal and moleCular CharaCteriStiCS

Caccese M.1_{, Lombardi G.}1_{, Simonelli M.}2_{, Fassan M.}3_{, Persico}

P.4_{, Lorenzi E.}4_{, Bertorelle R.}5_{, Gardiman M.P.}3_{, Bellu L.}6_,

Pambuku A.1_{, Santoro A.}4 _{and Zagonel V.}1

1_{Department of Clinical and Experimental Oncology, Veneto Institute of Oncol-}

ogy, IOV – IRCCS, Padova; 2_{Department of Biomedical Sciences, Humanitas}

University, Rozzano; 3_{Surgical Pathology Unit, Department of Medicine}

(DIMED), University-Hospital of Padua, Padova; 4_{Humanitas Cancer Center,}

Humanitas Clinical and Research Hospital, Rozzano; 5_{Immunology and Molec-}

ular Oncology Unit, Veneto Institute of Oncology, IOV - IRCCS, Padova; 6_Radia-

tion Therapy and Nuclear Medicine Unit, Veneto Institute of Oncology IOV IRCCS, Padova

Background: Immune-checkpoint inhibitors (ICI) repre- sent a new interesting approach in oncology. The presence of DNA MMRd would seem to be a predictor of ICI effi- cacy. We analyzed MMRd frequency in glioma PTS and its correlation with clinical, histological and molecular characteristics.

Methods: From July 2017 to May 2018, we prospectively analyzed histologically confirmed glioma PTS for the presence of MMRd by immunohistochemistry (IHC):

MSH2, MSH6, PMS2, MLH1. Clinical, histological and molecular characteristics (MGMT methylation and IDH mutational status, PD-L1 expression) were recorded. Chi- square test was used for analyzing their correlations with MMRd.

Result: 167 PTS were enrolled: 78% glioblastoma (GBM), 14% anaplastic astrocytoma (AA), 1% ependymoma, 2% anaplastic oligodendroglioma (OD) and 5% LGG. The analyses were assessed on tissue samples of first (82% of the cases), second surgery (18%). All PTS performing a second surgery received radiotherapy and temozolomide as first-line therapy. 134 PTS were analyzed for IDH sta- tus: 99 were IDH wt; 117 for MGMT status: 68 were meth- ylated. 27 PTS (16%) showed MMRd by IHC (MSH2 in 48%, MSH6 in 55.6%, PMS2 in 18.5% and MLH1 in 14.8%): 33% of AA, 14% of GBM, 33% of OD and 0% of LGG (p=0.2). MMRd was found in 13% and 32% on first and second surgery samples (p=0.03). PD-L1 expression analysis was performed in 60 cases: no expression was showed in 58% of cases, = 1% and <50% in 38%, > 50% in 10%. MMRd was not correlated with PD-L1 expression (p=0.3). MMRd was found in 10% and 29% of IDHwt and IDHmut gliomas (p=0.008); MMRd was showed in 10% and 21% of PTS with unmet and met- MGMT (p=0.1). Among MMRd tumors, 7 were also investigated by molecular analysis (PCR) of mononucleo- tide markers: in only 1 PT (14%) was confirmed MMRd in agreement with IHC analysis (p=0.1.).

Conclusions: We showed a small group of glioma PTS have MMRd by IHC, expecially at second surgery. Correlation was observed between IHC MMRd and IDH mutational status. No association was demonstrated between IHC MMRd and histology, MGMT status, PD-L1 expres- sion or molecular analysis of MMRd. A prospective study analyzing ICI efficacy in MMRd PTS should be warranted.

f03

high doSe Sib vmat radiotheraPy PluS temozolomide in

glioblaStoma PatientS: PhaSe i Study (iSide-bt-2) interim analySiS

Mignogna S.1_{, Ferro M.}2_{, Macchia G.}2_{, Cilla S.}3_{, Picardi V.}2_,

Mariangela B.2_{, Ferro M.}2_{, Ianiro A.}3_{, Monari F.}4_{, Buwenge M.}4_,

Arena E.2_{, Cucci E.}5_{, Sallustio G.}6_{, Valentini V.}7_{, Morganti A.G.}4_,

Deodato F.2 _{and Pozzo C.}8

1_{UOC di Oncologia Generale, Fondazione di Ricerca e Cura “Giovanni Paolo II”,}

Campobasso; 2_{UOC di Radioterapia, Fondazione di Ricerca e Cura “Giovanni}

Paolo II”, Campobasso; 3_{UO di Fisica Sanitaria, Fondazione di Ricerca e Cura}

“Giovanni Paolo II”, Campobasso; 4_{UOC di Radioterapia, DIMES, Università di}

Bologna, Bologna; 5_{UOC di Radiologia Fondazione di Ricerca e Cura “Giovanni}

Paolo II”, Campobasso; 6_{UOC di Radiologia, Fondazione di Ricerca e Cura “Gio-}

vanni Paolo II”, Campobasso; 7_{Gemelli ART, Fondazione Policlinico Gemelli}

IRCCS, Università Cattolica del Sacro Cuore, Roma; 8_{UOC di Oncologia Medica,}

Background: Glioblastoma multiform (GBM) is an aggressive and resitant disease with rather short overall survival. The multidisciplinary treatment consists of surgi- cal resection followed by post-operative chemoradiation with concurrent then adjuvant temozolomide (TMZ). Standard radiotherapy (RT) dose is 60 Gy in 2-Gy frac- tions (RTOG). Although TMZ can improve the efficacy of RT alone, a relapse is very common mostly within the irra- diation field. Several studies are exploring different RT schedules and doses. The aim of this phase I study was to determine the maximum tolerated dose (MTD) of RT with Volumetric Modulated Arc Therapy (VMAT) technique plus standard concurrent and sequential-dose TMZ in resected patients with GBM.

Methods: Histological proven GBM patients underwent VMAT dose escalation. VMAT was delivered over 5 weeks with the simultaneous integrated boost (SIB) technique to the two planning target volumes (PTVs) defined by adding 5-mm margin to the respective clinical target volumes (CTVs). CTV1 was defined by adding a 10-mm isotropic margin to the tumor bed plus any MR enhancing residual lesion; CTV2 was defined as the CTV1 plus 20-mm iso- tropic margin. Radiation dose was escalated to the PTV1 with the SIB-VMAT strategy. Four dose levels were planned for PTV1: level 1 (77.5/3.1 Gy), level 2 (80/3.2 Gy), level 3 (82.5/3.3 Gy) and level 4 (PTV1: 85/3.4 Gy); PTV2 was treated by the same dose (45/1.8 Gy). All treat- ments were delivered in 25 fractions. Patients were treated in cohorts of between three and six per group using a Phase I study design. The recommended dose was exceeded if two of the six patients in a cohort experienced dose-limit- ing toxicity within 3 months from treatment. TMZ chemo- therapy was administered according to Stupp’s protocol. Results: Eleven consecutive GBM patients (male/female: 7/4; median age: 59 years) were treated, 9 of them at first dose level, with none of them experiencing a dose-limiting toxicity (DLT) (grade >3). Being the MTD not exceeded, the PTV1 dose was escalated to the higher planned dose level (80/3.2 Gy) and accrual is actually ongoing. After a median follow-up time of 7 months, no grade >2 late neu- rological toxicity was recorded.

Conclusions: The SIB-VMAT technique plus TMZ was found to be feasible and safe at the recommended doses of 45Gy to PTV2 and 77.5Gy (biological effective dose –BED- of 157.6 Gy, alpha/beta 3) to PTV1 in the postop- erative treatment of patients with GBM. Efficacy data are as well under evaluation.

f04

third-line theraPy in

glioblaStoma: laSt but not leaSt

Mura A.1_{, Minichillo S.}2_{, Lanese A.}2_{, Scafati C.}2_{, Currà M.F.}2_,

Franceschi E.2_{, Tosoni A.}2_{, Lamberti G.}2_{, Paccapelo A.}2_,

Bartolini S.2_{, De Biase D.}3_{, Di Battista M.}2_{, Lombardo L.}2_,

Genestreti G.2_{, Visani M.}4 _{and Brandes A.A.}2

1_{Department of Medical Oncology, Bellaria Hospital, Azienda USL, Bologna;} 2_{Department of Medical Oncology, Bellaria Hospital Azienda USL, Bologna;} 3_{Department of Pharmacy & Biotechnology (Dipartimento di Farmacia e Bio-}

tecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bologna, Italy., Bologna; 4_{Department of Medicine (Dipartimento di}

Medicina Specialistica, Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna School of Medicine, Bolo- gna, Italy., Bologna

Background: About 21-62% of GBM patients (pts) access to 3rd _{line therapy. In this setting, there is no defined stand-}

ard. In this study we evaluated the outcome of pts who received 3rd _{line therapy for recurrent GBM.}

Methods: We analyzed data from our Institutional data warehouse from consecutive GBM pts who received 3rd

line therapy between 2005 and 2016.

Disease assessment was reviewed according to RANO criteria. Survival was calculated from diagnosis to death from any cause (OS) and from the beginning of 3rd _line

therapy to death from any cause (OS3). Progression-free survival was calculated from the beginning of 3rd _{line ther-}

apy to progression (PFS3).

Results: 184 pts (11.9%) received 3rd _{line therapy and}

were included in the study. Median age was 50.5 years (range: 20 to 72). Treatments administered in 3rd line were nitrosourea-based (NU) in 81 pts (44.0%), TMZ in 43 (23.4%), Bevacizumab (BEV) in 25 (13.6%) and carbo- platinum-etoposide (CE) in 35 (19%). mOS from GBM diagnosis was 30.3 months, median PFS3 was 2.7 months and median OS3 was 7.0 months. In univariate analysis, the BEV group showed longer mPFS3 (4.6 vs 2.4 months, p= .014) and mOS3 (8.0 vs 7.0 months, p= .038) with respect to NU (table 1). In multivariate analysis age <65 years (HR 0.50, 95%CI 0.30 – 0.84, p= .008) and mMGMT (HR 0.62, 95%CI 0.43 – 0.89, p= .01) significantly improved OS3.

Discussion: Favorable prognostic factors for pts who received 3rd _{line treatments are younger age and methyl-}

ated MGMT promoter. Third line therapy with BEV was associated with longer PFS3 and OS3.

f05

Should bevaCizumab be added to nitroSurea ChemotheraPy in PatientS with reCurrent

glioblaStoma? a SyStematiC review n mMGMT % PFS 3 (mos) OS 3 (mos)

BEV 25 41.2 4.6 8.0

CE 35 48.3 2.6 6.0

NU 81 47.5 2.4 7.0

and meta-analySiS of randomized trialS

Metro G.1_{, Costa C.}2_{, Fabi A.}3_{, Castrioto C.}4_{, Cenci N.}4_,

Monacelli G.5_{, Nardi Cesarini E.}2_{, Verzina A.}2_{, Romoli M.}2_,

Lupattelli M.6 _{and Eusebi P.}2

1_{Oncologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospe-}

daliera di Perugia, Perugia; 2_{Clinica Neurologica, Ospedale Santa Maria della}

Misericordia, Università di Perugia, Perugia; 3_{Oncologia Medica 1, Istituto Nazi-}

onale Tumori Regina Elena, Roma; 4_{Divisione di Neurochirurgia, Ospedale}

Santa Maria della Misericordia, Azienda Ospedaliera di Perugia, Perugia; 5_Onc-

ologia Medica, Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia, Perugia, Perugia; 6_{Radioterapia Oncologica, Ospedale Santa Maria}

della Misericordia, Azienda Ospedaliera di Perugia, Perugia

Background: Nitrosurea chemotherapy is to be consid- ered a standard treatment option for patients with glioblas- toma multiforme (GBM) whose disease recurs following Stupp regimen. On the other hand, antiangiogenic treat- ment with bevacizumab as single-agent has also been reported to be active in this clinical setting. We conducted a systematic review and meta-analysis of published trials in order to evaluate whether the addition of bevacizumab to nitrosurea could improve the clinical outcome of recur- rent GBM patients.

Materials and Methods: Trials published in english lan- guage between 2008 and 2018 were identified by an elec- tronic search of MEDLINE. We included retrospective and prospective studies (randomized and single-arm) that reported on patients with primary GBM who were treated with either nitrosurea alone or nitrosurea plus bevaci- zumab at first disease recurrence after Stupp regimen. Demographic data, objective response rate, median pro- gression-free survival (PFS), PFS rate at 6 months (PFS- 6), median overall survival (OS), 1-year OS and grade 3/4 toxicities were extracted. Pooled random effects analysis was performed and heterogeneity assessed.

Results: We pooled eligible PFS-6 data from 13 nitrosurea studies (n = 821) and 4 nitrosurea plus bevacizumab stud- ies (n = 570). The pooled PFS-6 did not significantly dif- fer between nitrosurea alone (25%, 95% CI = 19% to 32%) and nitrosurea plus bevacizumab treated patients (35%, 95% CI = 28% to 41%). Heterogeneity was large in both nitrosurea alone (I-squared = 73%) and nitrosurea plus bevacizumab studies (I-squared = 56%). When we focused on randomized studies we found a decrease in het- erogeneity and the pooled PFS-6 was significantly higher for nitrosurea plus bevacizumab treated patients (30%, 95% CI 26% to 35%, I-squared = 0%) compared to nitro- surea alone (21%, 95% CI 13% to 21%, I-squared = 3%). Only two randomized controlled studies provided head to head comparison, resulting in a higher risk of not reaching PFS-6 for nitrosurea alone (RR = 0.87, 95% CI = 0.77 to 0.98, I-squared = 45%).

Conclusions: The present meta-analysis shows that the addition of bevacizumab to nitrosurea significantly

improves PFS-6 in patients with recurrent GBM following Stupp regimen. Results on other key endpoints of clinical outcome, including OS, will be presented at the meeting.

f06

ComPrehenSive geriatriC

aSSeSSment (Cga) for outCome PrediCtion in elderly PatientS (PtS) with glioblaStoma (gbm): a mono-inStitutional exPerienCe

Bergo E., Lombardi G., Bellu L., Caccese M., Lettiero A., Tierno G., Pambuku A., Brunello A. and Zagonel V.

Istituto Oncologico Veneto - IRCCS, Padova

Background: Treatment for GBM elderly PTS is still a challenge in neuro-oncology. Clinical tools, including CGA, are needed for improving treatment decision and outcome. To date, few studies exploring the impact of CGA on outcome have been performed in these PTS. The aim of this study was to evaluate CGA as a prognostic tool in terms of PFS and OS in elderly GBM PTS.

Methods: we performed a retrospective analysis of elderly PTS ⩾ 65 years, treated at Veneto Institute of Oncology between January 2011 and January 2018, with newly his- tologically diagnosed GBM and receiving a baseline CGA after 3-4 weeks from surgery. CGA included the following domains: age, activities and instrumental activities of daily living (ADL, IADL), cognitive status (MMSE), mood (GDS), nutritional status (MNA), number of drugs, comor- bidity (cumulative Illness Rating Scale-CIRS), presence of geriatric syndromes, presence of caregiver. PTS were clas- sified according to Balducci’s criteria into Fit or Unfit (Frail and Vulnerable).

Results: 113 PTS were enrolled: 72 (64%) were male, KPS were ⩾ 70 in 90 PTS (80%); 37 PTS (33%) had a radical surgery, 63% partial surgery and 4% received a biopsy. 90 PTS (80%) received Stupp treatment, 16 (14%) temozolomide or radiotherapy alone and, only 7 (6%) received no treatment. MGMT methylation status was ana- lyzed in 96 PTS: 44% were metMGMT. According to CGA evaluation: 40 PTS (35.4%) were classified as Fit and 73 PTS (64.6%) Unfit. PFS was 11.2 (95% CI 6.0- 16.4) and 7.2 (95% CI 5.8-8.6) months for Fit and Unfit PTS (p=0.1). On multivariate analysis, adjusted for type of surgery, MGMT methylation status and type of therapy, PFS was significantly different between the two groups (HR=0.6, 95% CI 0.2-0.9; p=0.04). OS was 16.4 (95% CI 14.6-18.2) and 10.6 (95% CI 8.3-12.8) ms for Fit and Unfit PTS (p=0.04); on multivariate analysis the HR was 0.51 (95% CI 0.2-0.9; p=0.04).

Conclusions: CGA demonstrated significant outcome pre- diction in terms of OS and PFS, regardless of therapy. It could be a useful treatment decision-tool suggesting to

treat FIT PTS with radiochemotherapy while a prospective study to evaluate the best treatment in Unfit PTS should be warrant.

f07

the Continuum of Care Strategy for reCurrent gbm: doeS the SequenCe of treatmentS matter?

Minichillo S.1_{, Mura A.}1_{, Lanese A.}1_{, Scafati C.}1_{, Currà M.F.}1_,

Franceschi E.1_{, Tosoni A.}1_{, Lamberti G.}1_{, Paccapelo A.}1_{, Bartolini}

S.1_{, De Biase D.}2_{, Agati R.}3_{, Di Battista M.}4_{, Lombardo L.}1_,

Genestreti G.1_{, Visani M.}5 _{and Brandes A.A.}1

1_{Department of Medical Oncology, Bellaria-Maggiore Hospitals, Azienda USL,}

IRCCS Institute of Neurological Sciences, Bologna, Italy., Bologna; 2_Department

of Pharmacy & Biotechnology (Dipartimento di Farmacia e Biotecnologie) - Molecular Diagnostic Unit, Azienda USL di Bologna, University of Bologna, Bolo- gna, Italy., Bologna; 3_{Department of Neuroradiology, Bellaria Hospital, AUSL}

Bologna., Bologna; 4 _{Department of Medical Oncology, Bellaria-Maggiore Hos-}

pitals, Azienda USL, IRCCS Institute of Neurological Sciences, Bologna, Italy., Bologna; 5 _{Department of Medicine (Dipartimento di Medicina Specialistica,}

Diagnostica e Sperimentale) - Molecular Diagnostic Unit, Azienda USL di Bolo- gna, University of Bologna School of Medicine, Bologna, Italy., Bologna

Background: The improvement in the treatment of GBM (glioblastoma) patients (pts) has contributed to progres- sively increase the median life expectancy, being survival at 2 years in the range of 30-40%.

This survival increase has supported, as in other cancer types, the concept of continuum of care as the optimal pal- liative therapy strategy. However, the best treatment strat- egy after the first disease progression is unknown.

Methods: We retrospectively analyzed data from our Institutional data warehouse from consecutive GBM pts who received at least 2 line of systemic therapy at dis- ease progression after RT/TMZ. Survival was calculated from diagnosis to death from any cause (Overall Survival, OS)

Results: 1552 consecutive GBM pts underwent standard RT/TMZ from 2005 and 2016. One hundred eighty-four pts (11.9%) received at least 2 lines of systemic therapy at disease progression.

MGMT methylation status was available for 142 patients (77.2%): MGMT was methylated in 75 pts (mMGMT, 52.8%) and unmethylated in 67 (nmMGMT, 47.2%). We grouped patients by Bevacizumab (BEV) treatment as follows: pts who never received BEV (NoBEV, n=123), pts who received BEV in 2nd line

(BEV2, n=36), pts who received BEV in 3rd line (BEV3 n=21), pts who received BEV in 2nd and 3rd line (n=4). OS was significantly longer in the NoBEV than the BEV2 group (33.0 vs 24.7 months, p= .023). Treatments outcome is summarized in the Table.

Discussion: Continuum of care might have a role in the treat- ment of GBM pts. Future strategies should take into account the sequence of treatments for patients with recurrent GBM.

f08

the SoCioeConomiC imPaCt of gliomaS: a Survey queStionnaire

Scafati C., Lanese A., Mura A., Minichillo S., Currà M.F., Franceschi E., Tosoni A., Paccapelo A., Bartolini S., Di Battista M., Lombardo L., Genestreti G. and Brandes A.A.

Department of Medical Oncology, Bellaria Hospital, Azienda USL, Bologna

Background: Socioeconomic status (SES) is associated with survival in many cancers but the effect of disease on SES and access to care for patients with gliomas has not been well studied.

Methods: A questionnaire was designed and administered to 202 consecutive patients treated in our Institution, with diagnosis of diffuse glioma (grade II, II IV). The 22-item survey questionnaire included items related to demograph- ics, personal history, personal concern of cancer, impact of cancer on SES and self-consciousness. All responses were summarized descriptively. Frequency distributions of responses for each question were calculated.

Results: Completed surveys were returned by all the 202 glioma patients (male/female: 62.4% – 37.6%). Overall, 42.1% of patients still work, while 38.1% retired; 38.9% of patients retired due to the disease, 21.3% needed to reduce working time. In 46.3% of patients the disease had an impact on the economic status. Female patients were sig- nificantly less likely to feel attractive when compared with male patients (68.7% vs 37.8%, P=0.001). Moreover, sex- ual activity was worsened both in male and female patients (53.7% vs 43.8%, P=0.364).

Conclusions: The impact of gliomas on patients is burden- some and multidimensional. These diseases heavily impact SES and self-consciousness.

f09

CliniCal PrognoStiC faCtorS in low grade gliomaS: ConCordanCe between rtog and eortC Criteria

Lanese A., Lanese A., Scafati C., Mura A., Santino M., Currà M.F., Franceschi E., Tosoni A., Paccapelo A., Bartolini S., Balestrini D., Visani M., Di Battista M., Lombardo L., Genestreti G. and Brandes A.A.

Department of Medical Oncology, Bellaria Hospital, Azienda USL, Bologna

Treatment

sequence N Median OS(Months) 95% CI

No BEV 123 33.0 27.7–38.2

BEV2 36 24.7 17.6–31.8

BEV3 21 30.1 26.3–34.0

Background: Low grade gliomas (LGG) are a heteroge- neous group of brain primary tumors. The EORTC and the RTOG criteria are the most valuable scores to evaluate risk factors and for treatment decision. However, there is no data about concordance between criteria.

Methods: We conducted an analysis on LGG patients treated in our Institution from 1998 to 2015. The popula-

Nel documento ERBB2 mutations in hormone receptor positive primary breast cancers samples and in their matched endocrine-resistant recurrences. (pagine 116-122)